Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 10/20 | 0.52 |
| ▸ | GAA | P10253 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PIKFYVE | Q9Y2I7 | 2/20 | 0.52 |
| ▸ | FES | P07332 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 1/20 | 0.52 |
| ▸ | FRK | P42685 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.52 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL426316 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL10198704 | 1.00 | L3MBTL1 (0.56) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL13004729 | 0.92 | MAPT (0.51) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL1721328 | 0.91 | MAPT (0.50) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL1721324 | 0.91 | MAPT (0.50) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL1618007 | 0.88 | PIKFYVE (0.51) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL1617306 | 0.88 | PIKFYVE (0.54) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL1617304 | 0.88 | PIKFYVE (0.54) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL428496 | 0.87 | TYK2 (0.68) | L3MBTL1MAPTGAAALDH1A1PIKFYVE | |
| SCHEMBL428497 | 0.87 | TYK2 (0.68) | L3MBTL1MAPTGAAALDH1A1PIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | claimed |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | claimed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | claimed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1458687-A4 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2005-03-23 | — | — | EP | claimed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | claimed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| EP-1458687-A2 | PYRIMIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040048873-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP., A DELAWARE CORPORATIO | 2004-03-11 | — | — | US | disclosed |
| US-6693097-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-02-17 | — | — | US | disclosed |
| US-20030139403-A1 | Pyrimidine compounds | SHIONOGI BIORESEARCH CORP. | 2003-07-24 | — | — | US | disclosed |
| WO-2003047516-A2 | PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | L3MBTL1 4848/4885MAPT 238/4885GAA 2575/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | L3MBTL1 1129/4885MAPT 4316/4885GAA 3596/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | L3MBTL1 3725/4885MAPT 1747/4885GAA 1723/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | L3MBTL1 3725/4885MAPT 1747/4885GAA 1723/4885 |
| US-20110288081-A1 | PYRIMIDINE COMPOUNDS AND USES THEREOF | RORC, IL23R, ORC3 | L3MBTL1 3717/4885MAPT 4267/4885GAA 4823/4885 |
| US-20030139403-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | L3MBTL1 3489/4885MAPT 4042/4885GAA 4567/4885 |
| US-20040048873-A1 | Pyrimidine compounds | CBR1, CBR3, CCNO | L3MBTL1 3504/4885MAPT 4185/4885GAA 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.